Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies
Clinical trial NCT05981209 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05981209
- Sponsor
- Abdullah Khan
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-21
- Primary completion
- 2026-12-31
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.